Tag - FEMY

Developments

Femasys begins pivotal trial of non-surgical permanent birth control candidate

Femasys (NASDAQ:FEMY) initiated enrollment in a prospective multi-center pivotal trial to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The trial is designed to...

August 3, 2023

Developments

Enrollment tops 25% in Femasys FemaSeed de novo trial

Femasys (NASDAQ:FEMY) completed more than 25% of its targeted enrollment of 214 patient fertility cycles in its FemaSeed de novo trial. FemaSeed is the first and only first-line approach in development designed to...

November 29, 2022

Feature

Femasys innovating women’s reproductive health with minimally invasive, in-office technologies

Femasys (NASDAQ:FEMY) is on a road to disrupt traditional approaches to women’s reproductive health with proprietary diagnostics and devices that address global markets in infertility and permanent birth control.

August 30, 2022

Markets

Maxim starts Femasys at buy; PT $5

Maxim Group launched coverage of Femasys (NASDAQ:FEMY) with a “buy” rating and $5 price target. The stock closed at $1.30 on June 16. Femasys is developing treatments to address the two extremes of the women’s...

June 17, 2022

Tag - FEMY

Femasys begins pivotal trial of non-surgical permanent birth control candidate

Enrollment tops 25% in Femasys FemaSeed de novo trial

Femasys innovating women’s reproductive health with minimally invasive, in-office technologies

Maxim starts Femasys at buy; PT $5

General

More